Showing 5971-5980 of 6035 results for "".
- Shire Announces Sale of Oncology Business to Servier for $2.4 Billionhttps://modernod.com/news/shire-announces-sale-of-oncology-business-to-servier-for-2-4-billion/2480237/Shire announced that it has entered into a definitive agreement with privately held French pharmaceutical group Servier S.A.S. to sell its Oncology business for $2.4 billion. “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Swiss Advanced Vision Launches Active IOL Concept with Real-Time Autofocushttps://modernod.com/news/swiss-advanced-vision-launches-active-iol-concept-with-real-time-autofocus/2480257/Swiss Advanced Vision (SAV-IOL) has announced the launch of Project R-TASC (Real-Time Autofocus Servo Control), an active lens with real-time autofocus and wireless connectivity. Current lenses are fixed and suffer from optical compromises, such as light distribution, resolution, and visua
- Alcon to Present Robust Clinical Program, New Innovations at ASCRShttps://modernod.com/news/alcon-to-present-robust-clinical-program-new-innovations-at-ascrs/2480259/Alcon will showcase advancements in the cataract, glaucoma, and refractive spaces during the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting, taking place April 13-17 in Washington, D.C. The company will leverage nearly 90 scientific abstract presentations, several
- Alcon Introduces Systane Complete Solution for Dry Eyehttps://modernod.com/news/alcon-introduces-systane-complete-solution-for-dry-eye/2480262/Alcon has introduced Systane Complete, a new formula designed to provide soothing relief for every major type of dry eye. The new product joins the Systane family of dry eye drops as a first-line treatment option for people who suffer from evaporative dry eye, aqueous tear deficient dry eye, or m
- SIFI Announces Approval of Mini Well Ready IOL in Singaporehttps://modernod.com/news/sifi-announces-approval-of-mini-well-ready-iol-in-singapore/2480263/Italian ophthalmic company SIFI has announced the approval of the Mini Well Ready IOL by Singapore’s Health Science’s Authority. Mini Well Ready is an innovative, aspherical, EDOF, progressive IOL designed for the surgical correction of presbyopia. “It is today increasingly rec
- Dallas Lighthouse for the Blind to Merge With Envisionhttps://modernod.com/news/dallas-lighthouse-for-the-blind-to-merge-with-envision/2480267/Envision announced that it has acquired the Dallas Lighthouse for the Blind. Operations will continue as normal in Dallas, and the Dallas Lighthouse for the Blind name will be retained. Financial terms of the deal were not disclosed. The merger will have positive benefits both in Te
- Zepto Receives Award for Best Capsulotomy Technology 2017https://modernod.com/news/zepto-receives-award-for-best-capsulotomy-technology-2017/2480270/Mynosys Cellular Devices has announced that its flagship automated capsulotomy device, »Zepto, has been selected as the best capsulotomy technology by Cataract and Refrac
- Global Dry Eye Treatment Revenues to Grow to $4.9 Billion by 2022https://modernod.com/news/global-dry-eye-treatment-revenues-to-grow-to-49-billion-by-2022/2480272/Market Scope expects the global dry eye treatments market to grow at a healthy pace through 2022, as 2017 revenues of $3.7 billion climb to $4.9 billion. Revenues will climb most sharply in emerging markets and other developing nations where we forecast double-digit compounded annual growth rates